http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_751ea4e7fc6c6c2391cee1e472b4f77d
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Goldschmidt |
| name | Hartmut Goldschmidt |
| given-name | Hartmut |
| organization-name | Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Center of Tumor Diseases Heidelberg Germany Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and... §Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany;; ∥National Center of Tumour Diseases Heidelberg, Heidelberg, Germany 2Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; 4National Center of Tumor Diseases (NCT), Heidelberg, Germany. Department of Internal Medicine V University Clinic Heidelberg University of Heidelberg Germany Medizinische Klinik V, Universitätsklinikum Heidelberg and Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany. Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany. Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome,... Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;; National Center of Tumor Diseases, Heidelberg, Germany Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;; National Center for Tumor Diseases (NCT), Heidelberg, Germany; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany; Department of Oncology and Hematology, National Center for Tumor Diseases (NCT), Heidelberg, Germany From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York (D.M.... Thomas Schmitt, Hartmut Goldschmidt, Anja Freiberger, Johannes Hüsing, Martina Gronkowski, Markus Thalheimer, Le Hang Pelzl, Gerd Mikus, Jürgen Burhenne, Anthony D. Ho, and Gerlinde Egerer, Heidelberg University Hospital, Heidelberg; and Kai Neben, Klinikum Mittelbaden, Baden-Baden, Germany. §Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany Department of Haematology, Oncology and Rheumatology University of Heidelberg Heidelberg Germany; National Centre for Tumor Diseases Heidelberg Germany Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany, University Hospital Heidelberg and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Medical Department V, Section of Multiple Myeloma Heidelberg University Hospital Germany Heidelberg Medical University, Heidelberg, Germany; From the Department of Hematology and Oncology; and Department of Diagnostic and Interventional Radiology, University of Heidelberg; Department of Radiology, German Cancer Research Center; Department of Medical Physics in Radiology, German Cancer Research Center; Department of Biostatistics, German Cancer Research Center; and National Center for Tumor Diseases, Heidelberg, Germany. From the Tumor Immunology Program, The German Cancer Research Center, Heidelberg, Germany; the Department of Hematology and Oncology, The University Hospital Heidelberg, Heidelberg, Germany; the Department of Experimental Rheumatology, Medical Clinic, Charité, Humboldt University, Berlin, Germany; and the Department of Oncology, University Hospital Zurich, Zurich, Switzerland. University Hospital Heidelberg, Internal Medicine V & National Center for Tumor Diseases (NCT), Heidelberg 69120, Germany Internal Medicine V and National Center for Tumor Diseases (NCT) University Clinic Heidelberg Heidelberg Germany Abteilung Innere Medizin V, Hämatologie, Onkologie, Rheumatologie, Universitätsklinikum Heidelberg k Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Internal Medicine V University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg Germany 11Department of Internal Medicine V and National Center of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Center for Tumor Diseases, University of Heidelberg Heidelberg Germany Department of Internal Medicine V University of Heidelberg and National Center for Tumor Diseases Heidelberg Germany University of Heidelberg, Heidelberg, Germany; and Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany;; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; and Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; National Center for Tumor Diseases (NCT) German Cancer Consortium (DKTK) Heidelberg Germany Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Centre of Tumor Diseases Heidelberg Germany Tilmann Bochtler, Ute Hegenbart, Anja Seckinger, Christoph Kimmich, Hartmut Goldschmidt, Anthony D. Ho, Dirk Hose, and Stefan O. Schönland, Amyloidosis Center, University Hospital Heidelberg; Christina Kunz and Axel Benner, German Cancer Research Center; Martin Granzow and Anna Jauch, Institute of Human Genetics, University Heidelberg; and Hartmut Goldschmidt and Dirk Hose, National Center for Tumor Diseases, Heidelberg, Germany. Hematology, Oncology and Rheumatology University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases Heidelberg University Hospital Heidelberg Germany Medizinische Klinik V Universitaetsklinikum Heidelberg Heidelberg Germany Department of Medicine V, University of Heidelberg, Heidelberg, Germany Department of Hematology University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases (NCT) Heidelberg Germany Department of Haematology, Oncology, and Rheumatology University of Heidelberg Im Neuenheimer Feld 410, D‐69120 Heidelberg Germany Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Centre of Tumour Diseases University of Heidelberg Heidelberg Germany Division of Hematology/Oncology, Department of Internal Medicine, University of Heidelberg, Heidelberg; Amyloidosis Center, Department of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany; Medizinische Klinik V, Universitätsklinikum Heidelberg; Nationales Centrum für Tumorerkrankungen NCT Heidelberg Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany Department of Internal Medicine V; University of Heidelberg; Heidelberg Germany k Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany Medizinische Klinik, Abteilung Innere Medizin V, Universitätsklinikum Heidelberg und National Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany; National Center for Tumor Diseases (NCT) HeidelbergHeidelberg, Germany. Department of Haematology, Oncology, and Rheumatology University Hospital Heidelberg Heidelberg Germany Department of Internal Medicine V and National Center for Tumor Diseases, Heidelberg, Germany; and Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; National Center for Tumor Diseases (NCT), Heidelberg University Hospital Heidelberg Germany Department of Internal Medicine V National Center for Tumor Diseases, University of Heidelberg Heidelberg Germany University of Heidelberg, Heidelberg, Germany; *Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany;; †National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany; Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA;... Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Bo Björkstrand, Astrid Gruber, and Gösta Gahrton, Karolinska Institute at Huddinge and Solna, Stockholm, Sweden; Simona Iacobelli, Universitàdi Roma “Tor Vergata,” Rome; Franco Narni, University of Modena, Modena; Alberto Bosi, Ospedale di Careggi, Florence; Giuseppe Milone, Ospedale Ferrarotto, Catania; Paolo Corradini, University of Milano, Milano; Pellegrino Musto, Istituto Di Ricovero e Cura a Carattere Scientifico, Centro Riferimento Oncologico Basilicata, Rionero in Vulture, Italy; Ute Hegenbart... University Hospital Heidelberg, Internal Medicine V & National Center for Tumor Diseases, Heidelberg, Germany University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany. Department of Hematology/Oncology, University Hospital of Heidelberg, Heidelberg, Germany;; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Department of Medicine V Heidelberg University Hospital Heidelberg Germany; Department of Medical Oncology National Center for Tumor Diseases (NCT) Heidelberg Germany Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany + Nationales Centrum fur Tumorerkrankungen, Heidelberg, Germany Department of Hematology, Oncology and Rheumatology, University of Heidelberg; National Center for Tumor Diseases, Heidelberg Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany Medizinische Klinik V, University of Heidelberg, and National Center for Tumor Diseases, Heidelberg, Germany; Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg D-69120 GERMANY §Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; and; ¶Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany Section Multiple Myeloma Department Haematology, Oncology and Rheumatology University Hospital Heidelberg and National Center for Tumor Diseases Heidelberg Heidelberg Germany Department of Internal Medicine V University Medical Hospital and National Center of Tumor Diseases University of Heidelberg Heidelberg Germany Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Germany;; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany 3University Hospital Heidelberg and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany. Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany Department of Internal Medicine V University Clinic Heidelberg and National Center of Tumor Diseases Heidelberg Germany 2University of Heidelberg, Department of Hematology, Oncology and Rheumatology,; 5National Center for Tumor Diseases, Heidelberg, Germany 1Department of Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.; 4National Center for Tumor Diseases, Heidelberg, Germany. Multiple Myeloma Section, Department of Medicine V University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases (NCT) Heidelberg Germany Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Henk M. Lokhorst, Utrecht Medical Center, Utrecht, the Netherlands; Hartmut Goldschmidt, University Hospital of Heidelberg, Heidelberg, Germany; Laura Rosiñol, Joan Bladé, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Michele Cavo, Paola Tacchetti, Elena Zamagni, Istituto di Ematologia Seràgnoli, Università degli Studi di... Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Centre for Tumor Diseases Heidelberg Germany From the Institute of Cancer Research, London; Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury; University of Leeds, Leeds, United Kingdom; Erasmus Medical Center, Rotterdam; University Medical Center, Utrecht, the Netherlands; University of Heidelberg, Heidelberg, Germany; Cedars Sinai, Los Angeles, CA; and University of Minnesota. Minneapolis, MN. Department of Medicine V Heidelberg University Heidelberg Germany; National Center for Tumor Diseases Heidelberg University Heidelberg Germany Department of Medicine V University Hospital Heidelberg Heidelberg Germany David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej... Department of Internal Medicine V University Hospital Heidelberg Heidelberg Germany Department of Internal Medicine V, University Medical Hospital and National Center of Tumor Diseases, Heidelberg, Germany; Kai Neben, Anna Jauch, Jens Hillengass, Nicola Lehners, Martin Granzow, Marc S. Raab, and Anthony D. Ho, University of Heidelberg; Thomas Hielscher, German Cancer Research Center; and Anja Seckinger, Hartmut Goldschmidt, and Dirk Hose,University of Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany. University Hospital Heidelberg, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany University of Heidelberg, Department of Internal Medicine V, Heidelberg, Germany Division of Multiple Myeloma, Universitatsklinikum Heidelberg, Heidelberg, Germany; 15University Hospital, Internal Medicine V and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany. GMMG‐Study Group, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany Authors' Affiliations: 1CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Université MONTPELLIER1, UFR Médecine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg; and 5Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Authors' Affiliations: 1CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Université MONTPELLIER1, UFR Médecine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg; and 5Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany Heidelberg Medical University, Heidelberg, Germany. National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany; Division of Hematology/Oncology, Department of Internal Medicine V, and From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut für Humangenetik, Universitätsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Nîmes, Nîmes, France. Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany; National Center for Tumour Diseases, University of Heidelberg, Heidelberg, Germany Department of Internal Medicine V University Clinic Heidelberg Heidelberg Germany; Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg Heidelberg Germany Department of Hematology, Oncology and Rheumatology University of Heidelberg Heidelberg Germany; National Center for Tumor Diseases University of Heidelberg Heidelberg Germany Department of Internal Medicine V, and; National Center of Tumor Diseases, Heidelberg, Germany; and Department of Medicine V, Hematology/Oncology/Rheumatology, University of Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany Department of Medicine V University of Heidelberg Heidelberg Germany; National Center for Tumor Diseases (NCT) Heidelberg Germany From the Roswell Park Cancer Institute, Buffalo; New York–Presbyterian Hospital, New York, NY; Alta Bates Cancer Center, Berkeley, CA; University of Pennsylvania Cancer Center, Philadelphia, PA; Emory University, Atlanta, GA; Millennium Pharmaceuticals Inc, Cambridge; Dana-Farber Cancer Institute, Boston, MA; University Hospital Rotterdam, Rotterdam, the Netherlands; Hospital Claude Huriez, Lille; Hotel Dieu Hospital, Nantes, France; Hadassah University Hospital, Jerusalem, Israel; Universitaetsklinikum... Authors' Affiliations: 1Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; 2Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; 3Abteilung für Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 4INSERM, U1040; 5CHU Montpellier, Institute of Research in Biotherapy; and 6Université Montpellier 1, UFR Médecine, Montpellier, France; Authors' Affiliations: 1Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; 2Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; 3Abteilung für Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 4INSERM, U1040; 5CHU Montpellier, Institute of Research in Biotherapy; and 6Université Montpellier 1, UFR Médecine, Montpellier, France Department of Internal Medicine, Division of Hematology/Oncology, Amyloidosis Clinic, University of Heidelberg, Heidelberg;; National Center for Tumor Diseases, Heidelberg, Germany Division of Hematology/Oncology/Rheumatology, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany;; National Center for Tumor Diseases, Heidelberg, Germany; and Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany; National Center for Tumor Diseases, University Hospital Heidelberg Germany Department of Internal Medicine V University of Heidelberg Heidelberg, Germany Internal Medicine V and National Center of Tumor Diseases, University Clinic Heidelberg, Heidelberg, Germany; Authors' Affiliations: 1Department of General Pathology, Institute of Pathology; and 2Department of Medicine V, Heidelberg University Hospital; 3Max Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and University of Heidelberg; 4Department of Neuropathology, Institute of Pathology, University of Heidelberg and the Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ); and 5Department of Translational Oncology and 6Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Authors' Affiliations: 1Department of General Pathology, Institute of Pathology; and 2Department of Medicine V, Heidelberg University Hospital; 3Max Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) and University of Heidelberg; 4Department of Neuropathology, Institute of Pathology, University of Heidelberg and the Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ); and 5Department of Translational Oncology and 6Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany n Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Philippe Moreau, University Hospital Hôtel-Dieu; Jean-Luc Harousseau, Centre Rene Gauducheau, Nantes; Michel Attal, Centre Hospitalier Universitaire (CHU) Toulouse; Hervé Avet-Loiseau, CHU Rangueil, Toulouse; Gerald Marit, University Hospital of Bordeaux, Bordeaux; Cyrille Hulin, CHU Nancy, Nancy; Thierry Facon, Hopital Claude Huriez; Xavier Leleu, University Hospital of Lille, Lille; Denis Caillot, CHU Dijon, Dijon; Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours; Jean-Yves Mary... Heidelberg Medical University and National Center for Tumor Diseases Heidelberg Germany From the Department of Internal Medicine V and Department of Transplantation Immunology, University of Heidelberg, Germany. University Hospital Heidelberg, Heidelberg, Germany Department of Internal Medicine V University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases (NCT) Heidelberg Heidelberg Germany Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany;; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Department of Medicine V University Hospital Heidelberg Heidelberg Germany; National Center for Tumor Diseases Heidelberg University Hospital Heidelberg Germany 1Department of Hematology, Oncology, and Rheumatology, University of Heidelberg; Departments of; 5National Center of Tumor Diseases, Heidelberg, Germany; and Authors' Affiliations: 1Department of Internal Medicine V, 2Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V; 3National Center for Tumor Diseases, University of Heidelberg; 4Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ); 5Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; 6Department of Medical Oncology, Dana-Farber Cancer Institute; 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; 8Center for Nanomedicine and Theranostics & Department of Chemistry; and 9Center for Microbial Biotechnology, Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark; Authors' Affiliations: 1Department of Internal Medicine V, 2Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V; 3National Center for Tumor Diseases, University of Heidelberg; 4Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ); 5Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; 6Department of Medical Oncology, Dana-Farber Cancer Institute; 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; 8Center for Nanomedicine and Theranostics & Department of Chemistry; and 9Center for Microbial Biotechnology, Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark Medizinische Klinik V and; National Center for Tumor Diseases, Heidelberg, Germany; Department of Medicine V, Multiple Myeloma Section, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany Medical Department V, Heidelberg Myeloma Center, Heidelberg University Hospital, National Centre for Tumor Diseases (NCT), Heidelberg, Germany Department of Haematology, Oncology and Rheumatology University Hospital Heidelberg Heidelberg Germany; National Centre for Tumour Diseases (NCT) University Hospital Heidelberg Heidelberg Germany; GMMG Study Group at University Hospital Heidelberg Heidelberg Germany Department of Medical Oncology National Center for Tumor Diseases Heidelberg Germany; Department of Medicine V Heidelberg University Hospital Heidelberg Germany Medizinische Klinik und Poliklinik V, Universität Heidelberg. hartmut_goldschmidt@med.uni-heidelberg.de Department of Internal Medicine V University of Heidelberg Heidelberg Germany; National Center for Tumor Diseases University of Heidelberg Heidelberg Germany Department of Internal Medicine V University of Heidelberg Heidelberg Germany From the University of Heidelberg, Department of Hematology/Oncology/ Rheumatology, and the German Cancer Research Center, Central Unit Biostatistics, Heidelberg, Germany. 1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; 2National Center for Tumor Diseases Heidelberg, University of Heidelberg, Heidelberg, Germany. Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; National Center of Tumor Diseases, Heidelberg, Germany Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases Heidelberg Heidelberg Germany |
Incoming Links
Total number of triples: 582.